A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure–response relationships: a proof-of-concept study with alectinib
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-024-04698-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Lishi Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Net…. Hauptthemen laut MEDLINE: Piperidines, Carbazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
In exposure–response analyses of oral targeted anticancer agents, longitudinal plasma trough concentrations are often aggregated into a single value even though plasma trough concentrations can vary over time due to dose adaptations, for example. The aim of this study was to compare joint models to conventional exposure–response analyses methods with the application of alectinib as proof-of-concept.
Methods
Joint models combine longitudinal pharmacokinetic data and progression-free survival data to infer the dependency and association between the two datatypes. The results from the best joint model and the standard and time-dependent cox proportional hazards models were compared. To normalize the data, alectinib trough concentrations were normalized using a sigmoidal transformation to transformed trough concentrations (TTC) before entering the models.
Results
No statistically significant exposure–response relationship was observed in the different Cox models. In contrast, the joint model with the current value of TTC in combination with the average TTC over time did show an exposure–response relationship for alectinib. A one unit increase in the average TTC corresponded to an 11% reduction in progression (HR, 0.891; 95% confidence interval, 0.805–0.988).
Conclusion
Joint models are able to give insights in the association structure between plasma trough concentrations and survival outcomes that would otherwise not be possible using Cox models. Therefore, joint models should be used more often in exposure–response analyses of oral targeted anticancer agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
- Department of Biometrics, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- Department of Medical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- Department of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
- Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. a.huitema@nki.nl.
Zitieren
APA
Lin, L., van der Noort, V., Steeghs, N., Ruiter, G., Beijnen, J. H., & Huitema, A. D. R. (2024). A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure–response relationships: a proof-of-concept study with alectinib. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04698-w
Vancouver
Lin L, van der Noort V, Steeghs N, Ruiter G, Beijnen JH, Huitema ADR. A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure–response relationships: a proof-of-concept study with alectinib. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04698-w
BibTeX
@article{Lin2024,
author = {Lin, Lishi and van der Noort, Vincent and Steeghs, Neeltje and Ruiter, Gerrina and Beijnen, Jos H and Huitema, Alwin D R},
title = {A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure–response relationships: a proof-of-concept study with alectinib},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04698-w}
}
EUVIMED